secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124598
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma Q3 net loss $15M; cash $80.5M; amends AstraZeneca deal with $114.3M milestone potential
--------------------------------------------------------------------------------

- Amended AstraZeneca license agreement modifies development milestones; potential future payments up to $114.3M in cash and ADSs; issued 2.04M shares and paid $0.5M.
- Q3 net loss $15.0M vs $6.5M YoY, driven by $6.4M foreign exchange loss; R&D down 12% to $3.2M.
- Cash $80.5M as of Sep 30, 2024 (up from $57.4M Dec 2023); expected to fund operations into 2027.
- Setrusumab received FDA Breakthrough Therapy designation for osteogenesis imperfecta; Phase 3 topline data expected 2025.
- Alvelestat remains on track to be Phase 3-ready by end of 2024; partnership discussions ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000095017024124598/0000950170-24-124598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000095017024124598/mreo-20241108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer